Plain-English translation of NCT07126782 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether allogeneic gamma-delta T cells—special immune cells grown in the laboratory—can help treat acute myeloid leukemia (AML) that persists after a bone marrow transplant. Researchers will give participants the treatment twice a week for at least four cycles to see if it is safe and whether it helps eliminate remaining leukemia cells.
After a bone marrow transplant, some patients still have small amounts of leukemia remaining that can't be seen with regular tests. This trial exists because researchers believe that the new treatment might help the immune system recognize and destroy these remaining leukemia cells, potentially improving survival and reducing the chance of the cancer coming back.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the specially grown immune cells twice each week for at least four cycles (approximately 8 weeks or longer). During treatment, you will have regular visits to receive the infusions and undergo blood tests and other monitoring to check how well the treatment is working and whether you experience any side effects. The study will track your health closely throughout the treatment period and beyond to evaluate whether the treatment helps eliminate remaining leukemia cells.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~10 participants
Started
July 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Erlie Jiang, M.D.;Ph.D
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.